[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612559":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":31,"locations":41,"responsibleParty":68,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":11,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":94,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Common variable immunodeficiency","EXPERIMENTAL",null,[13],"Other: blood sample",{"label":15,"type":16,"description":17,"interventionNames":18},"Controls","ACTIVE_COMPARATOR","Healthy controls",[13],[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"blood sample","48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation",[9,15],[25,28],{"name":26,"affiliation":5,"role":27},"Jean-François VIALLARD, Prof","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":5,"role":30},"Jonathan VISENTIN, Prof","STUDY_DIRECTOR",[32,37],{"name":26,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","(0)5.57.65.64.83","+33","jean-françois.viallard@chu-bordeaux.fr",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Carine LOPEZ","(0)5.24.54.91.32","carine.lopez@chu-bordeaux.fr",[42],{"facility":43,"status":11,"city":44,"state":11,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CHU de Bordeaux - service de médecine interne","Pessac","France","FR",{"type":48,"coordinates":49},"Point",[50,51],-0.6324,44.80565,{"lat":51,"lon":50},[54,55,56,57,60,62,64,66],{"name":26,"role":33,"phone":34,"phoneExt":35,"email":36},{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},{"name":26,"role":27,"phone":11,"phoneExt":11,"email":11},{"name":58,"role":59,"phone":11,"phoneExt":11,"email":11},"Estibaliz LAZARO, Prof","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":11,"phoneExt":11,"email":11},"Carine GREIB, MD",{"name":63,"role":59,"phone":11,"phoneExt":11,"email":11},"Camille PROT-LEURENT, MD",{"name":65,"role":59,"phone":11,"phoneExt":11,"email":11},"Pierre DUFFAU, Prof",{"name":67,"role":59,"phone":11,"phoneExt":11,"email":11},"Emmanuel RIBEIRO, MD",{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100612559","peripheral-helper-t-cells-in-common-variable-immunodeficiency-100612559",false,"NCT07255157","Peripheral Helper T-cells in Common Variable ImmunoDeficiency","Deciphering the Role of Peripheral Helper T-cells in Common Variable ImmunoDeficiency Pathophysiology in Patients With Non-infectious Complications","TAPDI","Inclusion Criteria:\n\n* Male or female;\n* Age ≥ 18 years;\n* Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level \\\u003C5 g\u002FL, combined with low IgM- and\u002For IgA-isotype concentrations \\\u003C0.4 g\u002FL or \\\u003C0.7 g\u002FL, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);\n* Being affiliated to health insurance;\n* Willing to participate and to sign informed consent.\n\nExclusion Criteria:\n\n* Patients on corticosteroids and\u002For immunosuppressants;\n* Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;\n* Patients with an active chronic infection;\n* Pregnant or breastfeeding women;\n* Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.",true,"ALL","18 Years",{"count":82,"type":83},60,"ESTIMATED","INTERVENTIONAL",[86],"NA","The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.",[89],"Common Variable Immunodeficiency",[91,92,93],"common variable immunodeficiency","peripheral helper T cells","B cells","NOT_YET_RECRUITING","2025-12-02",{"date":97,"type":98},"2025-12-10","ACTUAL",{"date":100,"type":83},"2025-12",{"date":102,"type":83},"2027-12",{"name":5,"class":6},1]